Ulcerative colitis is treated with a range of medications that work through fundamentally different mechanisms, and choosing the right one depends on how severe your disease is, which part of your colon is affected, and how you’ve responded to previous treatments. The options span from oral anti-inflammatory pills taken daily to intravenous infusions given every few weeks to brand-new oral drugs that interrupt immune signaling at a molecular level. Most people start with milder therapies and escalate if needed, though the trend in recent years has been to use more powerful medications earlier when the disease looks aggressive.
Aminosalicylates as the Starting Point
For mild to moderate ulcerative colitis, the first medication your gastroenterologist will likely reach for is mesalamine, a type of 5-aminosalicylic acid (5-ASA). These drugs work locally in the colon lining rather than throughout your whole body. They tamp down inflammation by blocking the production of inflammatory chemicals like prostaglandins and leukotrienes, and they also interfere with signals from certain immune-system proteins that would otherwise keep the inflammatory cycle going.1PubMed Central. The role of mesalamine in the treatment of ulcerative colitis
Mesalamine comes in oral tablets, granules, suppositories, and enemas, and the formulation matters because the drug needs to be released right where the inflammation is. Newer multi-matrix (MMX) formulations deliver the drug more precisely to the inflamed lining of the colon and can be taken once a day, which helps people actually stick with the regimen.2PubMed. MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations Response rates for active mild-to-moderate disease generally fall between 40% and 70%, with full remission in roughly 15% to 20% of patients. Dosing is important: about 4.8 grams per day is considered optimal for active flares, while around 2.4 grams per day works for keeping remission going long term.3PubMed Central. The role of mesalamine in the treatment of ulcerative colitis
Corticosteroids for Flares
When a flare hits and aminosalicylates aren’t enough, corticosteroids enter the picture. These are powerful anti-inflammatory drugs meant for short-term use to get a flare under control. Traditional steroids like prednisone are effective but come loaded with side effects, from weight gain and mood swings to bone thinning and blood sugar spikes, which is why doctors try to taper you off them as quickly as possible.
Budesonide MMX is a newer oral steroid designed to act more locally in the colon while causing fewer body-wide side effects. A pooled analysis of three trials involving 900 people found that about 15% of those taking budesonide MMX 9 mg achieved combined clinical and endoscopic remission at eight weeks, compared to 7% on placebo. The benefit was strongest in people with left-sided disease. And while budesonide did suppress morning cortisol levels somewhat, the average values stayed within the normal range, and glucocorticoid-related side effects weren’t significantly different from placebo.4Cochrane Library. Oral budesonide for induction of remission in ulcerative colitis One catch: standard oral budesonide was actually less effective than oral mesalamine for inducing remission in one head-to-head trial, so budesonide MMX specifically is the formulation that has shown benefit in UC.5Cochrane Library. Oral budesonide for induction of remission in ulcerative colitis
The key thing to understand about steroids is that they are bridge therapy, not a long-term solution. If you find yourself needing repeated steroid courses or unable to taper off without relapsing, your doctor should be discussing the next step up in treatment.
Thiopurine Immunomodulators
For people who keep relapsing or who can’t get off steroids, azathioprine (and its cousin 6-mercaptopurine) has been a mainstay for decades. These drugs suppress the immune system more broadly than aminosalicylates do, which means they take longer to kick in, often two to three months, but they can keep the disease quiet for years. In a long-term follow-up study, about 60% of patients achieved sustained clinical benefit on azathioprine. Among those who stayed on it for more than five years, that figure climbed to roughly 86%, and very few of them needed to escalate to a biologic or undergo surgery.6Journal of Crohn’s and Colitis. Long-term Efficacy and Safety of Azathioprine in Ulcerative Colitis
In one study of patients who were steroid-dependent or had frequent relapses, starting azathioprine cut the average number of relapses from about 3.3 to under 1, and steroids could be stopped entirely in 12 out of 15 patients who had been on them long-term.7PubMed Central. Long term results of use of azathioprine in patients with ulcerative colitis in India The downside is side effects: pancreatitis, liver inflammation, low blood counts, and hair loss prompted drug withdrawal in a meaningful number of patients in the same study.8PubMed Central. Long term results of use of azathioprine in patients with ulcerative colitis in India The risk of bone marrow suppression varies by genetics, and testing for a specific enzyme (TPMT) before starting can help predict who’s at higher risk.9PubMed. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis
Anti-TNF Biologics
Biologic medications represent a major leap in UC treatment. The first class to arrive, and still the most widely used, targets a protein called tumor necrosis factor alpha (TNF-alpha) that drives gut inflammation. Infliximab, adalimumab, and golimumab are the three anti-TNF agents approved for UC. A network meta-analysis pooling data across trials found that anti-TNFs roughly doubled the odds of achieving and maintaining remission compared with placebo, and all three individual drugs showed benefit for both inducing and maintaining remission and clinical response.10PubMed Central. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis
Infliximab is given by intravenous infusion, typically at weeks zero, two, and six for induction, then every eight weeks. Adalimumab and golimumab are self-injected under the skin. The choice often comes down to practical factors: some people prefer the convenience of self-injection at home, while others do well with infusion-center visits where a nurse monitors them.
When Biologics Stop Working
One of the frustrating realities of biologic therapy is that it can lose effectiveness over time. Your body can develop antibodies against the drug itself, which neutralize it and speed up its clearance from your system. In one prospective study, about 11% of patients on biosimilar infliximab developed these anti-drug antibodies, and every single patient who developed them had drug levels that were too low to be therapeutic.11PubMed Central. Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
What happens next depends on the level of those antibodies. Research has shown that patients with high levels of anti-drug antibodies did better when switched to a different anti-TNF agent, while patients with low or no antibodies responded better to simply increasing the dose of their current drug.12Clinical Gastroenterology and Hepatology. Association Between Levels of Drug and Antidrug Antibodies and Outcomes of Interventions in Inflammatory Bowel Disease Patients With Loss of Response to Infliximab or Adalimumab This is why therapeutic drug monitoring, where blood is drawn to check drug levels and antibody status, has become an important tool. Expert consensus supports using it proactively during anti-TNF therapy, at least once during the induction phase and periodically during maintenance, to catch problems before they lead to a full-blown relapse.13Clinical Gastroenterology and Hepatology. Therapeutic Drug Monitoring of Biologic Therapy in Inflammatory Bowel Disease: Expert Consensus Statements Proactive monitoring appears to help avoid that secondary loss of response and improve long-term outcomes.14PubMed Central. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
Gut-Selective Therapies
Vedolizumab works through an entirely different strategy than anti-TNFs. Instead of blocking an inflammatory protein circulating throughout the body, it blocks a receptor on immune cells that lets them travel specifically into the gut wall. This gut-selective approach means the rest of your immune system stays more intact, which in theory translates to fewer infections and other side effects.15PubMed. Vedolizumab as induction and maintenance therapy for ulcerative colitis Safety data has generally backed this up, with vedolizumab showing a favorable safety profile across studies.16Gut. The safety of vedolizumab for ulcerative colitis and Crohn’s disease
The trade-off is speed. Vedolizumab tends to work more slowly than anti-TNFs, which can be a problem if you need rapid relief. It’s approved for moderate-to-severe UC and is given by intravenous infusion.17PubMed. The safety of vedolizumab for the treatment of ulcerative colitis For people who’ve already failed an anti-TNF, vedolizumab offers a mechanistically distinct alternative, and some clinicians now use it as a first-line biologic in patients where safety concerns are paramount.
IL-23 Inhibitors
The newest wave of biologics targets interleukin-23, a cytokine that sits upstream in the inflammatory cascade. Ustekinumab, which blocks both IL-12 and IL-23, was the first in this class approved for UC. It has demonstrated good efficacy for both inducing and maintaining remission and mucosal healing, with a safety profile that shows no increased risk of side effects compared to placebo. It works in patients who have never tried a biologic and in those who’ve already failed one, making it a flexible option in the treatment lineup.18PubMed Central. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges
Behind ustekinumab are newer selective IL-23 inhibitors that block only the p19 subunit of IL-23, leaving IL-12 function untouched. Agents like guselkumab, risankizumab, and mirikizumab are at various stages of approval and investigation. Early network meta-analysis data suggests that guselkumab and risankizumab show strong efficacy compared to placebo, though confidence intervals are still wide for some of these newer agents.19PubMed. Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis This class is moving fast, and more approvals are expected in the near future.
Oral Small Molecules
Not every advanced therapy requires an injection or infusion. JAK inhibitors, including tofacitinib and upadacitinib, are pills that block Janus kinase enzymes involved in immune signaling. They work fast, which is appealing for people in the middle of a stubborn flare. A large real-world comparison found that both tofacitinib and upadacitinib had safety profiles broadly comparable to other advanced therapies in UC, with one notable exception: both carried higher rates of herpes zoster (shingles) reactivation compared to IL-23-targeted drugs.20Journal of Crohn’s and Colitis. P1084 Safety of tofacitinib and upadacitinib compared to other advanced therapies in ulcerative colitis: a large real-world comparison Interestingly, thromboembolic event rates were actually lower with JAK inhibitors than with anti-TNFs in this analysis, which pushes back against earlier safety concerns that had led to regulatory caution around tofacitinib in older patients with cardiovascular risk factors.
Sphingosine-1-phosphate (S1P) receptor modulators, including ozanimod and etrasimod, represent another oral option. They work by trapping certain immune cells in lymph nodes so they can’t migrate to the inflamed colon.21PubMed Central. Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety Because they don’t suppress the immune system as broadly as some other therapies, their side effect profile tends to be milder, though they can slow heart rate at initiation and require cardiac monitoring when starting.
Managing Acute Severe Flares
About 15% to 25% of people with UC will experience at least one episode of acute severe colitis, which requires hospitalization and intravenous steroids. When IV steroids fail, typically after about three to five days, the decision gets serious: either escalate to salvage medical therapy or proceed to surgery. The two main rescue options are infliximab and cyclosporine, a calcineurin inhibitor. Both work, but infliximab has increasingly become the preferred choice because of its practical advantages and potentially better long-term outcomes.22PubMed. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
A retrospective study comparing the two found that patients treated with infliximab had a significantly lower rate of later colectomy: about 26% ultimately needed surgery compared with 67% in the cyclosporine group.23PubMed Central. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study Even with the best medical rescue therapy, though, roughly 20% to 30% of patients with acute severe UC will still need colectomy.24PubMed Central. Salvage Therapy in Acute Severe Ulcerative Colitis: Current Practice and a Look to the Future Tofacitinib’s fast onset of action makes it an emerging rescue option as well, particularly for patients who have already been on a biologic.25PubMed. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
What “Remission” Actually Means Now
The goalposts for treating UC have shifted considerably. It used to be enough to feel better and have fewer symptoms. Today, gastroenterologists aim for mucosal healing, meaning the colon lining looks normal or near-normal on colonoscopy, and increasingly for histological healing, where even microscopic inflammation has resolved. Patients who achieve endoscopic mucosal healing have relapse-free survival rates that are measurably higher than those who still have visible inflammation, and the benefit is even more pronounced when looking at complete endoscopic normalization versus mild residual redness.26PubMed. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes
Histological remission appears to go even further. A five-year analysis found that achieving histological remission independently protected against needing steroids, needing biologics, being hospitalized for a severe flare, and overall disease progression.27PubMed Central. Histological remission as a reliable predictor of clinical outcomes in patients with ulcerative colitis after conventional therapy: a 5-year analysis A meta-analysis of over 1,500 patients confirmed that histological healing predicted better long-term outcomes than endoscopic healing alone.28Inflammatory Intestinal Diseases. Mucosal Healing of Ulcerative Colitis Based on Endoscopic Diagnosis, Histopathology, and Mucosal Inflammatory Mediators This matters practically because it means your doctor might recommend staying on or adjusting a medication even when you feel fine if biopsies show ongoing low-level inflammation.
Medications During Pregnancy
UC often affects people during their reproductive years, so medication safety during pregnancy is a common concern. Active disease during pregnancy carries more risk than most UC medications do, so the general principle is that keeping the disease in remission matters more than avoiding drugs. Aminosalicylates are considered low-risk. Thiopurines are widely used during pregnancy despite crossing the placenta, because uncontrolled inflammation tends to be worse for the pregnancy than the drug itself. Anti-TNF biologics are also considered compatible with pregnancy, though some doctors time the last dose to avoid high drug levels in the baby at delivery.
Vedolizumab’s safety during pregnancy has been less studied, but case reports and growing clinical experience suggest that continuing it through pregnancy and breastfeeding carries adverse event rates similar to anti-TNF therapy.29PubMed Central. Vedolizumab Safety During Pregnancy and Lactation in a Patient with Ulcerative Colitis: A Case Report Methotrexate is the clear exception: it must be stopped well before conception because it causes birth defects. JAK inhibitors and S1P modulators are also generally avoided during pregnancy due to limited safety data.
Treating Children with UC
Children with UC face the same basic treatment ladder but with some important differences. Dosing for aminosalicylates is weight-based, typically around 36 to 40 mg per kilogram per day, though pediatric data remains more limited than in adults and recommendations are largely borrowed from adult studies.30PubMed Central. Pediatric ulcerative colitis: current treatment approaches including role of infliximab Infliximab has been used in children for years. More recently, a phase 3 trial showed that high-dose adalimumab produced meaningful remission rates in children with moderate-to-severe UC, with about 60% of children in the high-dose induction group achieving remission at week eight and 45% maintaining remission at one year.31The Lancet Gastroenterology & Hepatology. Efficacy and safety of adalimumab in children with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, multicentre, double-blind, phase 3 study Growth and development add another layer to treatment decisions in pediatric UC; chronic steroid use is particularly problematic for children because of its effects on bone growth and height.
Biosimilars and Cost
The original anti-TNF biologics have now gone off patent, and biosimilars, which are essentially equivalent versions produced by different manufacturers, have entered the market at lower prices. A study from Germany found that switching from originator biologics to biosimilars produced no difference in health outcomes while lowering costs.32PubMed. Physician-Led Switching From Reference Biologics to Biosimilars: What is the Effect on Selected Health-Related Outcomes and Costs for Patients With Inflammatory Bowel Disease in Germany? Canadian provinces that introduced mandatory biosimilar switching estimated savings of nearly $119 million in a single year, with projections of over $450 million annually if the policy were adopted nationwide.33Journal of the Canadian Association of Gastroenterology. An Update on Anti-TNF Biosimilar Switching—Real-World Clinical Effectiveness and Safety If your doctor proposes switching you from a brand-name biologic to a biosimilar, the evidence supports it being a safe move.
Vaccines and Immunosuppression
Because many UC medications suppress the immune system to varying degrees, vaccination timing matters. The general recommendation is to get all necessary vaccines, including those with live components, at least four weeks before starting immunosuppressive therapy if possible. Once you’re on an immunosuppressant, live vaccines like the measles-mumps-rubella (MMR) vaccine or the live shingles vaccine should be avoided because the weakened virus in the vaccine could potentially cause the disease it’s meant to prevent.34PubMed Central. Vaccination in patients with inflammatory bowel diseases Inactivated vaccines, like the flu shot and COVID-19 vaccines, remain safe to give but may produce a slightly weaker immune response. Checking your hepatitis B, varicella, and pneumococcal vaccination status at diagnosis, before any immune-suppressing treatment begins, is one of the practical steps that often gets overlooked in the rush to control a new flare.
Fecal Microbiota Transplantation
The idea that reshaping the gut’s bacterial community could treat UC has generated considerable interest. Fecal microbiota transplantation (FMT) involves introducing stool from a healthy donor into the patient’s colon. A randomized trial found that FMT achieved steroid-free remission in 32% of participants compared to 9% with a control transplant.35JAMA. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial That’s encouraging, but systematic reviews have found that while FMT can help induce clinical remission, maintaining that remission and achieving endoscopic healing remain challenging.36Scientific Reports. Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis FMT for UC is still considered experimental by most guidelines, and questions about optimal donor selection, frequency of treatment, and long-term safety are far from settled. Dietary approaches have also been studied as add-on therapies alongside standard medications rather than replacements, acknowledging that diet alone doesn’t control active UC the way drugs do.37PubMed Central. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis